10x Genomics, Inc. (Nasdaq: TXG) has announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., developer of foundational In Situ technologies, based in Boston, for cash and stock consideration of $350 million. The announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August.
Latham & Watkins LLP represents 10x Genomics, Inc. in both acquisitions. The team was led by Bay Area corporate partner Mark Bekheit, with Bay Area associates Tessa Bernhardt, Kaitlyn Fulcher and Nimrah Khan. Advice was also provided on intellectual property matters by Bay Area partner Anthony Klein, with Bay Area associates Cassandra Wang, and Heather Lui; on life sciences matters by Bay Area associate Jekkie Kim, with New York associate Jiqiang Lin; on tax matters by Bay Area partner Grace Lee, with Washington, D.C. associate Amy Feinberg and Boston associate Jeremiah Cowen; on benefits and compensation matters by Bay Area partner Ashley Wagner, with Bay Area associate Erik Ward; on privacy matters by Bay Area counsel Heather Deixler, with London associate Calum Docherty.